No­var­tis isn’t mess­ing around with CAR-T, and it has a promis­ing next-gen ther­a­py to help prove it

The cen­ter ring at AS­CO this week­end will fea­ture CTL019, No­var­tis’ lead CAR-T that ap­pears to be head­ed to a land­mark ap­proval in a mat­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.